Across TCGA pan-cancer cohorts, KANK2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KANK2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher KANK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KANK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

DLBC, SCLC, and CESC are the cancer types where KANK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
READ	OS	Median	All	0.653	0.930	.033	6	view →
UCEC	DFS	Median	All	0.953	0.628	.041	2	view →
SKCM	DFS	Median	II,III,IV	0.866	0.556	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: KANK2 tumor-vs-normal RNA expression · all KANK2 data types